Research and Markets has announced the addition of the "Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Pipeline Review, H2 2016" report to their offering.
Neuronal Acetylcholine Receptor Subunit Beta 2 pipeline Target constitutes close to 11 molecules. Out of which approximately 9 molecules are developed by Companies and remaining by the Universities/Institutes.
Neuronal Acetylcholine Receptor Subunit Beta 2 - Pipeline Review, H2 2016, outlays comprehensive information targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Neuronal acetylcholine receptor subunit beta-2 is a protein encoded by the CHRNB2 gene. Acetylcholine binds to this receptor. This results in extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeable to sodium ions. The molecules developed by Companies in Phase II, Preclinical and Discovery stages are 1, 4 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.
Furthermore, this report also reviews key players involved in Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.
Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/kq2qhs/neuronal
Related Topics: Central Nervous System Drugs
View source version on businesswire.com: http://www.businesswire.com/news/home/20160920005862/en/Business Wire
Last updated on: 20/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.